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IS, and patients with LVEF ≥ 58 % had fewer incidences 
of the endpoint than patients with LVEF < 58 %. In conclu-
sion, lack of IS or LVEF < 58 % should be a predictor of 
future ADHF and all-cause mortality.
Keywords Aortic blood flow · Diastolic dysfunction · 
Ejection fraction · Inertia stress · Heart failure
Introduction
The blood in the aorta, once set in motion, will continue 
in motion because of inertia until the heart stops it [1]. In 
late systole, when left ventricular (LV) muscle shorten-
ing has reached a limit but its tension-generating ability 
for the LV wall is still maintained, the inertia of the blood 
flowing out of the left ventricle causes rapid end-systolic 
unloading of the left ventricle, producing a much smaller 
LV end-systolic volume, much greater LV elastic recoil 
force, and much speeded LV relaxation [2–4]. Inertia stress 
(IS) is defined as pressure (P) decay augmented by the 
effect of the inertia of blood flowing out of the left ven-
tricle on a phase plot of P (dP/dt vs. P) during late sys-
tole and early diastole. Thus, lack of IS of late systolic 
aortic flow is associated with abnormal LV relaxation in 
patients with coronary artery disease (CAD) and atypi-
cal chest pain [4]. LV diastolic dysfunction carries a sub-
stantial risk of subsequent development of heart failure 
(HF) and reduced survival, even when it is asymptomatic 
[5–11]. IS is observed in left ventricles with good systolic 
function, but not in all left ventricles with left ventricular 
ejection fraction (LVEF) ≥ 50 % [4]. LVEF ≥ 50 % has 
been defined as preserved or normal LV systolic function 
[9]. Although approximately one-half of patients with HF 
have preserved LVEF [5, 12], some epidemiological studies 
Abstract Based on our previous observation, inertia 
stress (IS) of late systolic aortic flow was often observed 
in left ventricles with relatively higher left ventricular (LV) 
ejection fraction (EF). Most left ventricles with relatively 
lower LVEF did not have IS. Accordingly, lack of IS may 
correlate with LV diastolic dysfunction through the loss of 
LV elastic recoil and may contribute to the pathogenesis of 
heart failure (HF) and reduced survival. We enrolled 144 
consecutive patients that underwent cardiac catheterization 
for the diagnosis of coronary artery disease. Left ventricu-
lar ejection fraction (LVEF) was obtained from left ven-
triculography. The IS was calculated from the LV pressure 
(P)−dP/dt relation. The study endpoint of this retrospective 
outcome-observational study was combined subsequent 
acute decompensated heart failure (ADHF) and all-cause 
mortality. During the follow-up period (median 6.1 years), 
seven unscheduled hospitalizations for ADHF and nine 
all-cause deaths were observed. The event-free survival 
rate was significantly higher among patients with IS than 
among patients without IS (log-rank, p = 0.001). On a mul-
tivariate Cox regression analysis, lack of IS was a prime 
predictor of the endpoint during follow-up (hazard ratio: 
6.98; 95 % confidence interval: 1.48–33.03; p = 0.01). An 
LVEF ≥ 58 % was a surrogate indicator for the presence of 
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have demonstrated a reduced distribution of higher LVEF 
patients with acute decompensated heart failure (ADHF) 
[13, 14]. On the other hand, LVEF has been accepted as 
a prognostic indicator in patients with CAD [15]. Accord-
ingly, this study had two aims: to identify the association of 
a lack of IS with subsequent ADHF and all-cause mortal-
ity in patients that underwent cardiac catheterization for the 
assessment of CAD; and to investigate whether we were 
able to predict the existence of IS using LVEF as a surro-
gate in such patients.
Materials and methods
Patients
The study patients consisted of 144 consecutive patients 
that underwent diagnostic cardiac catheterization to evalu-
ate CAD using a catheter-tipped micromanometer from 
January 2004 to June 2006. All patients had symptoms sug-
gestive of angina pectoris and/or clinical signs of CAD, 
including positive electrocardiographic changes during 
exercise, abnormal myocardial perfusion scintigraphic find-
ings, and a previous history of myocardial infarction (MI) 
or coronary revascularization. Patients with renal insuf-
ficiency (serum creatinine ≥ 1.5 mg/dL), atrial fibrillation 
or flutter, artificial pacemaker, hemodynamically signifi-
cant valvular disease, a post-prosthetic valve replacement 
condition, idiopathic dilated or hypertrophic cardiomyo-
pathy, ADHF, or acute coronary syndrome were excluded. 
According to the findings of coronary angiography and left 
ventriculography, 126 patients had CAD: 36 without prior 
MI and 90 with prior MI. CAD was defined as at least 50 % 
narrowing of the luminal diameter of one or more of the 
major coronary arteries, as determined by selective coro-
nary angiography. Prior MI was diagnosed on the finding of 
localized LV wall motion abnormality using biplane con-
trast left ventriculography with related electrocardiographic 
changes. Of the 90 MI patients, 46 had anterior-wall MI, 
26 had inferior-wall MI, and 18 had combined anterior- 
and inferior-wall MI. The remaining 18 patients (those not 
identified as having CAD) had neither significant coronary 
stenosis nor LV wall motion abnormality, but had atypical 
chest pain.
All studies were performed while patients were receiv-
ing cardiac medications. In describing patient characteris-
tics, hypertension was defined as systolic blood pressure 
of at least 140 mmHg and/or diastolic blood pressure of 
at least 90 mmHg or being treated with antihypertensive 
drugs. Diabetes mellitus was diagnosed when the fasting 
blood glucose level was greater than 126 mg/dL or when 
the patient was treated with blood glucose-lowering medi-
cine. Hypercholesterolemia was defined as a low-density 
lipoprotein cholesterol level exceeding 140 mg/dL or being 
treated with cholesterol-lowering medicine. This study was 
performed in a retrospective manner, and data were col-
lected from our database. The Ethical Guidelines Commit-
tee of Nagoya City University Graduate School of Medical 
Sciences approved the study protocol. Written informed 
consent for future data analysis regarding the cardiac cath-
eterization data was obtained from all patients at the time 
of cardiac catheterization.
Cardiac catheterization
Before contrast material was injected into the left ventricle 
or coronary arteries, LV pressure (P) waves were obtained 
with a catheter-tipped micromanometer (SPC-454D, Millar 
Instrument Co., Houston, TX) and recorded on a polygraph 
system (RMC-3000; Nihon Kohden Inc., Tokyo, Japan) as 
analog P signals. The P signals were sent to a digital data 
recorder (NR-2000, Keyence, Osaka, Japan) at a sampling 
interval of 2 ms, as we have reported elsewhere [3, 4, 8, 16, 
17]. dP/dt was obtained by differentiating digitally the LV 
P with respect to time, and peak (−dP/dt) was defined as 
the maximum negative value of dP/dt. The time constant 
Tw was computed by applying a monoexponential fitting 
with zero asymptote to the LV P decay [18]. Another time 
constant of isovolumic LV P decay, Tp, was defined as the 
negative inverse slope of the relation between dP/dt and P 
on a phase loop. The intermediate data points between peak 
(−dP/dt) and the minimum pressure in the phase plane 
were fitted to a rectilinear line using the method of least 
squares, dP/dt_linear = −kP + C (k > 0),
where k and C were constants to be estimated.
We excluded the first several data points after peak 
(−dP/dt) and those before the minimum P, because these 
data points deviated considerably from the linear fitting. 
We conducted this exclusion as follows. We took approxi-
mately 20 data points on the intercorporate P−dP/dt data 
starting from peak (−dP/dt). dP/dt was obtained at regu-
lar sampling intervals of P. From these points, we chose 
approximately 10 successive points, fitted a straight line 
to this set of points using the method of least squares, and 
calculated the standard error of the estimate. We repeated 
this procedure for all possible sets of the same number 
of successive points, and selected the set that yielded the 
minimum standard error of the estimate. From this set, we 
calculated the least squares values of k and C. The time 
constant Tp was given by Tp = 1/k [2, 4]. The element 
1/k was computed as the negative inverse slope of the best 
linear-fitting line (dP/dt_linear) between points a and b 
(Fig. 1). Points a and b indicate the start and end points of 
the dP/dt_linear for the slope of the relation between dP/dt 
and P during isovolumic relaxation. A loop obtained from 
a patient with IS is shown in Fig. 1a, and a loop obtained 
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from a patient without IS is shown in Fig. 1b. The shaded 
area A shown in the Fig. 1a is defined as the area between 
the measured P–dP/dt curve and the dP/dt_linear,
A = integral_P(a)∧P(c)(dP/dt − dP/dt_linear)dP
where P(a) is the pressure at point a and P(c) is the pres-
sure at point c which is defined as the intersection of P–dP/
dt curve and dP/dt_linear.
The point d was determined as the crossing point of the 
vertical line that passes the points (P0, 0) and peak (−dP/
dt), and the extended dP/dt_linear that passes the points a 
and b. The area divided by the vertical distance between 
(P0, 0) and point d is equal to the amount of pressure decay 
augmented by the effect of the inertia of blood flowing out 
of the left ventricle, and is defined as the IS of late systolic 
aortic flow [2, 4].
IS (mmHg) = A/distance between (P0, 0) and point d
The theoretical background to calculating IS in the 
phase plane was proposed by Sugawara et al. [2]. A little 
fluctuation was observed on the obtained phase loops, so 
that a small amount of IS may be erroneously calculated 
in some patients without having an apparently observed 
bump (grey area, Fig. 1a) in those loops around the time 
of peak (−dP/dt). The consensus we reached by reviewing 
the phase loops in our previous study was that we were able 
to confirm the existence of the bump in phase loops from 
patients with computed IS ≥ 0.5 mmHg (66.65 Pa) [4]. 
Thus, in the present study, we followed the previous defini-
tion that patients with computed IS ≥ 0.5 mmHg had IS 
and patients with calculated IS < 0.5 mmHg did not have 
IS. LV end-diastolic pressure was also determined. Biplane 
contrast left ventriculography was performed immediately 
after the pressure measurements. The method of Chapman 
et al. [19] was employed to calculate LV end-systolic and 
end-diastolic volumes. Then, LVEF was determined.
Pressure measurements using a catheter-tipped micro-
manometer in left-sided cardiac catheterization are essen-
tial in order to measure IS. Obtaining these pressure meas-
urements is difficult in daily clinical practice, because the 
procedure is invasive and using a catheter-tipped micro-
manometer is considerably expensive. As reported, IS is 
observed in left ventricles with relatively good systolic 
function [2, 4]. LVEF is a standardized parameter of LV 
systolic function that is obtained using echocardiography 
noninvasively, as well as conventional left ventriculogra-
phy. Thus, we attempted to seek the best threshold value of 
LVEF to distinguish whether the left ventricle has IS of late 
systolic aortic flow using the receiver operating characteris-
tic (ROC) curve analysis.
Statistical analysis
SPSS statistical software (version 17.0, SPSS Inc., Chi-
cago, IL) was used for statistical analysis. Triglyceride 
level was summarized as median and interquartile range 
(IQR) (25th to 75th percentiles). Other data are pre-
sented as mean ± standard deviation or frequency (%). 
Fig. 1  Left ventricular (LV) pressure (P)–first derivative of LV P 
(dP/dt) relationship (phase loop). Loops were obtained from patients 
with (a) and without (b) inertia stress (IS). The negative inverse slope 
of the best linear-fitting line (dP/dt_linear) between points a and 
b is equal to the time constant of exponential pressure decay dur-
ing isovolumic relaxation (Tp). The Tp was 56.3 ms in panel a and 
83.1 ms in panel b. Grey shading area (A) in the left panel denotes 
an area enclosed by the measured P−dP/dt curve and the dP/dt_lin-
ear, A = integral_P(a)∧P(c)(dP/dt − dP/dt_linear)dP, where P(a) is 
the pressure at point a and P(c) is the pressure at point c which is 
defined as the intersection of P−dP/dt curve and dP/dt_linear. The 
area A divided by the vertical distance between (P0, 0), and point d 
is equal to the amount of pressure decay augmented by the effect of 
the inertia of blood flowing out of the left ventricle, and is defined as 
the IS. The IS was 3.6 mmHg (479.9 Pa) in panel a and 0.12 mmHg 
(16.0 Pa) in panel b
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Relationships between two parameters were evaluated 
using Spearman’s correlation coefficients by ranks. Differ-
ences in parameters between two groups were compared 
using Student’s unpaired t test or the Mann–Whitney U test, 
as appropriate. A difference in incidence was compared 
using the Chi-squared test. For event-free survival analy-
sis, Kaplan–Meier curves were generated and compared by 
use of the log-rank test. We calculated hazard ratios (HRs) 
derived from the Cox proportional hazard model to identify 
predictors of combined subsequent HF and all-cause mor-
tality. The variables entered into the model were sex, age 
≥65 years, prior MI, LVEF <50 %, Tw ≥ 48 ms, and with 
or without IS. Differences with p < 0.05 were considered 
statistically significant.
Results
A total of 144 patients were enrolled (age 65.8 ± 8.9 years, 
116 men and 28 women). Clinical characteristics for all 
patients and subgroup demographics are shown in Tables 1 
and 2. There were no significant differences in age, sex, 
height, weight, mean blood pressure, heart rate, or sub-
scribed medicine between patients with subsequent ADHF 
and all-cause death and patients without those events. 
Compared with patients without events during the follow-
up period, patients with events had significantly lower 
LVEF and significantly longer LV relaxation time constants 
Tw and Tp. The group with events had significantly higher 
prevalence of prior MI and absence of IS than the group 
without events.
During the follow-up period (median 6.1 years), seven 
unscheduled hospitalizations due to ADHF and nine all-
cause deaths were observed (Table 3). The combined end-
point of subsequent ADHF and all-cause deaths occurred 
in 6 of 108 patients (5.6 %) with IS and 10 of 36 patients 
(27.8 %) without IS. The cause of non-cardiac death was 
cancer in all patients with or without events. Only one case 
with IS that died due to cardiac death was a sudden death; 
this patient underwent coronary bypass surgery. A Kaplan–
Meier plot showed that the incidence of the combined end-
point of subsequent ADHF and all-cause mortality was 
significantly lower among patients with IS than among 
patients without IS (log-rank, p = 0.001; Fig. 2a).
There were also no significant differences in age, sex, 
height, weight, mean blood pressure, heart rate, or sub-
scribed medicine between patients who reached another 
combined endpoint of subsequent ADHF and cardiac 
death and patients who did not (Supplementary Tables S1 
and S2). The occurrence of such an endpoint was signifi-
cantly lower in patients with IS than in patients without IS 
(log-rank, p = 0.011; Fig. 3a). The incidence of subse-
quent ADHF was lower in patients with IS than in patients 
without IS (log-rank, p = 0.016; Fig. 4a). Again, no sig-
nificant differences in age, sex, height, weight, mean blood 
pressure, heart rate, or subscribed medicine were observed 
between the patient groups (Supplementary Tables S3 and 
S4). Multivariate Cox regression analyses indicated that 
lack of IS was the predictor of the combined endpoint of 
subsequent ADHF and all-cause mortality (HR: 6.98; 95 % 
confidence interval [CI]: 1.48–33.03; p = 0.01), the com-
bined endpoint of subsequent ADHF and cardiac death 
(HR: 20.3, 95 % CI: 2.37–174, p = 0.006), and subsequent 
ADHF (HR: 22.3, 95 % CI 1.42–350, p = 0.03) during the 
follow-up period (Table 4).
The area under the curve (AUC) for LVEF to predict an 
absence of IS of late systolic aortic flow was 0.94 (95 % CI: 
0.90–0.98, p < 0.001). From the receiver ROC curve analy-
sis, an LVEF value of 58 % had 87 % sensitivity and 83 % 
specificity for predicting an absence of IS (Fig. 5). Other 
LVEF values indicated in the ROC curve were 57 and 62 % 
(Fig. 5). An LVEF value of 57 % had 87 % sensitivity and 
81 % specificity for predicting an absence of IS, and an 
Table 1  Comparisons of clinical characteristics and hemodynamic 
variables
Data represent mean ± standard deviation or frequency
LV left ventricular, LVEF left ventricular ejection fraction, Tw left 
ventricular relaxation time constant calculated by Weiss’s method, Tp 
left ventricular relaxation time constant calculated from phase loop, 
IS inertia stress
a The combined endpoint was defined as subsequent acute decom-
pensated heart failure and all-cause mortality
Characteristic All patients Without eventsa With events p
Number 144 128 16
Male/female 116/28 102/26 14/2 0.46
Age (years) 65.8 ± 8.7 65.5 ± 8.8 67.8 ± 7.8 0.33
Height (cm) 162.3 ± 8.1 162.3 ± 8.3 162.2 ± 6.1 0.97
Weight (kg) 63.9 ± 10.4 64.4 ± 10.6 60.2 ± 7.0 0.13
Body surface  
area (m2)
1.71 ± 0.16 1.71 ± 0.17 1.66 ± 0.11 0.24
Body mass index 
(kg/m2)
24.2 ± 3.3 24.4 ± 3.3 22.9 ± 2.6 0.09
Heart rate (beats/
min)
66.8 ± 10.7 66.7 ± 10.4 67.9 ± 13.2 0.68
Mean blood  
pressure 
(mmHg)
93.9 ± 14.1 94.1 ± 14.2 92.2 ± 13.8 0.61
LVEF ejection 
fraction (%)




14.1 ± 5.0 13.8 ± 4.7 17.1 ± 5.9 0.012
Tw (ms) 46.0 ± 9.1 45.3 ± 8.9 51.9 ± 8.6 0.005
Tp (ms) 78.0 ± 27.0 75.9 ± 25.8 94.8 ± 31.1 0.008
Lack of IS (%) 25 20.3 61.5 0.005
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LVEF value of 62 % had 84 % sensitivity and 83 % speci-
ficity for this purpose. Among these three possible threshold 
values, the LVEF value of 58 % was characterized by both 
the greatest sensitivity and the greatest specificity. In addi-
tion, an LVEF value of 48 % had 100 % sensitivity and 56 % 
specificity, and an LVEF value of 67 % had 58 % sensitiv-
ity and 100 % specificity for predicting an absence of IS. An 
LVEF value <48 % predicts an absence of IS with negative 
predictive value of 100 %. An LVEF value >67 % predicts an 
existence of IS with positive predictive value of 100 %.
Left ventricular ejection fraction <58 % was signifi-
cantly associated with the combined endpoints of future 
ADHF and all-cause mortality (log-rank, p = 0.02, 
Fig. 2b); however, it was not significantly associated 
with the combined endpoint of subsequent ADHF and 
cardiac death (log-rank, p = 0.17, Fig. 3b). LVEF <58 % 
was also significantly related to the subsequent ADHF 
(log-rank, p = 0.047, Fig. 4b). LVEF <50 % had no sig-
nificant relationships to these three endpoints (Figs. 2c, 
3c, 4c).
Table 2  Comparisons of 
clinical characteristics, 
underlying diseases, and 
medications
Data represent mean ± standard deviation or frequency or median and interquartile range (IQR). Blood 
samples were obatained at fasting
HDL high-density lipoprotein, LDL low-density lipoprotein, Hb hemoglobin, MI myocardial infarction, 
PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, BNP brain natriuretic pep-
tide, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium chan-
nel blocker
Characteristic All patients Without events With events p
Total cholesterol (mg/dL) 187.5 ± 36.4 188.1 ± 36.0 190.6 ± 46.8 0.80
Triglycerides (mg/dL) 125 [IQR, 90–189] 128 [IQR, 91–195] 119.5 [IQR, 80.8–154] 0.26
HDL cholesterol (mg/dL) 45.6 ± 13.1 45.6 ± 12.3 44.3 ± 16.2 0.70
LDL cholesterol (mg/dL) 111.6 ± 32.8 112.0 ± 32.2 121.1 ± 37.8 0.30
Glucose (mg/dL) 117.1 ± 45.8 117.7 ± 48.0 112.1 ± 23.0 0.64
HbA1c (%) 6.5 ± 1.9 6.4 ± 1.9 6.6 ± 1.8 0.65
Serum creatinine (mg/dL) 0.90 ± 0.36 0.90 ± 0.37 0.93 ± 0.22 0.77
Hemoglobin (g/dL) 13.3 ± 1.5 13.5 ± 1.5 12.3 ± 2.6 0.06
Hypertension (%) 43.1 43.0 43.8 0.95
Hypercholesterolemia (%) 68.2 68.4 62.5 0.89
Diabetes mellitus (%) 32.6 32.8 31.3 0.90
Prior MI (%) 62.5 59.4 87.5 0.03
Prior heart failure (%) 13.2 14.1 6.3 0.38
Prior PCI (%) 40.3 41.4 31.3 0.44
Prior CABG (%) 8.3 7.8 12.5 0.52
Diuretics (%) 17.6 19.0 6.3 0.21
Statins (%) 59.0 59.4 56.3 0.76
ACEIs or ARBs (%) 35.2 35.9 25.0 0.36
β-blockers (%) 41.5 41.3 43.8 0.85
CCBs (%) 23.9 23.8 25.0 0.92
Table 3  The number of patients that reached the study endpoints
All data are presented as numbers
IS inertia stress
Patients with IS Patients without IS Total patients
Endpoint 108 36 144
All-cause mortality 4 5 9
Cardiac death 1 2 3
Non-cardiac death 3 3 6
Hospitalization due to acute decompensated heart failure 2 5 7
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Discussion
In the present study, we demonstrated that lack of IS of 
late systolic aortic flow is an independent predictor of 
subsequent ADHF and all-cause mortality in patients 
with CAD and atypical chest pain. An LVEF value of 
<58 % was able to detect an absence of IS with adequate 
sensitivity and specificity. Furthermore, LVEF <58 % was 
significantly associated with subsequent ADHF and all-
cause mortality. However, LVEF <50 % had no signifi-
cant relationship with this combined endpoint, although 
LVEF = 50 % is a well-recognized threshold value of 
LVEF to divide patients into those with preserved LVEF 
and those with reduced LVEF.
Fig. 2  Kaplan–Meier curves 
for the combined endpoint of 
subsequent acute decompen-
sated heart failure (ADHF) and 
all-cause death in patients with 
inertia stress (IS) (a), left ven-
tricular ejection fraction (LVEF) 
≥58 % (b), and LVEF ≥ 50 % 
(c). The combined endpoint-free 
survival rate was significantly 
higher in patients with IS than 
in those without IS. It was also 
higher in patients with LVEF 
≥58 % than those with LVEF 
<58 %. However, no significant 
difference in the endpoint-free 
survival rate was observed 
between patients with LVEF 






































































Fig. 3  Kaplan–Meier curves 
for the combined endpoint of 
subsequent acute decompen-
sated heart failure and cardiac 
death in patients with inertia 
stress (IS) (a), left ventricular 
ejection fraction (LVEF) ≥58 % 
(b), and LVEF ≥ 50 % (c). The 
combined endpoint-free survival 
rate was significantly higher in 
patients with IS than in patients 
without IS. No significant 
differences in the combined 
endpoint-free survival rate were 
observed between the patients 
with LVEF ≥58 % and patients 
with LVEF <58 %, or between 
the patients with LVEF ≥50 % 
and patients with LVEF <50 %
740 Heart Vessels (2016) 31:734–743
1 3
Fig. 4  Kaplan–Meier curves 
for subsequent acute decom-
pensated heart failure (ADHF) 
in patients with inertia stress 
(IS) (a), left ventricular ejection 
fraction (LVEF) ≥58 % (b), and 
LVEF ≥50 % (c). ADHF-free 
survival rate was significantly 
higher in patients with IS than 
in patients without IS. It was 
also higher in patients with 
LVEF ≥58 % than in patients 
with LVEF <58 %. No signifi-
cant difference in ADHF-free 
survival rate was observed 
between patients with LVEF 
≥50 % and patients with LVEF 
<50 %
Table 4  Factors associated 
with events in univariate and 
multivariate analyses
CI confidence interval, MI myocardial infarction, LVEF left ventricular ejection fraction, Tw left ventricular 
relaxation time constant calculated by Weiss’s method, IS inertia stress
Univariate Multivariate
Hazard ratio 95 % CI p Hazard ratio 95 % CI p
Subsequent acute decompensated heart failure and all-cause mortality
 Age ≥ 65 years 1.38 0.48–4.00 0.55
 Male 1.26 0.28–5.58 0.76
 Prior MI 3.24 0.73–14.4 0.12
 LVEF < 50 % 2.18 0.75–6.41 0.16
 Tw ≥ 48 ms 3.40 1.22–9.43 0.02 2.34 0.72–7.58 0.16
 Lack of IS 4.65 1.68–12.9 0.003 6.98 1.48–33.0 0.01
Subsequent acute decompensated heart failure and cardiovascular death
 Age ≥ 65 years 2.19 0.45–10.6 0.33
 Male 1.69 0.34–8.38 0.52
 Prior MI 3.39 0.42–27.7 0.25
 LVEF < 50 % 1.44 0.29–7.171 0.65
 Tw ≥ 48 ms 2.64 0.70–10.0 0.15
 Lack of IS 5.15 1.27–20.8 0.02 20.3 2.37–174 0.006
Subsequent acute decompensated heart failure
 Age ≥ 65 years 1.52 0.30–7.88 0.62
 Male 2.50 0.46–13.6 0.29
 Prior MI 2.46 0.29–21.1 0.41
 LVEF < 50 % 2.17 0.40–11.91 0.37
 Tw ≥ 48 ms 2.77 0.63–12.7 0.19
 Lack of IS 6.34 1.22–32.9 0.03 22.3 1.42–350 0.03
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Effect of IS on prognosis
In this study, patients that were hospitalized for ADHF or 
with all-cause death had significantly lower LVEF, longer 
LV relaxation time constants (Tw and Tp), and higher prev-
alence of lack of IS than patients without these events dur-
ing the follow-up period. The IS is produced by left ven-
tricles with good systolic function [2]. Thus, lack of IS is 
related to loss of elastic recoil in the left ventricle, which 
in turn results in the deterioration of LV relaxation [4]. 
This means that even with LVEF ≥50 %, the left ventri-
cle would not have good LV systolic function if it does not 
have IS. In other words, left ventricles with good systolic 
function enhance their relaxation through the elastic recoil 
of the left ventricle caused by the IS [4]. Published reports 
indicate that even in patients with LVEF > 50 %, impaired 
LV systolic function (which was evaluated using mitral 
annular excursion during systole or peak mitral annular 
velocity during systole) is associated with LV diastolic dys-
function and HF [20–22]. In the present study, patients that 
reached the combined endpoint of subsequent ADHF and 
all-cause mortality had a higher prevalence of prior MI than 
those without. This finding is compatible with our previ-
ous report that the lack of IS observed in CAD patients fre-
quently accompanies prior MI and LV apical asynergy [4]. 
Subsequent ADHF was rare among patients with IS, and 
most patients with IS died because of non-cardiac reasons. 
Thus, left ventricles with IS are unlikely to develop sub-
sequent ADHF. In a multivariate Cox proportional hazard 
model, lack of IS was an independent predictor of subse-
quent ADHF and all-cause mortality. In contrast, LVEF 
<50 % (a standard threshold of LV systolic dysfunction) 
and Tw ≥48 ms (a definition of abnormal LV relaxation by 
the European Society of Cardiology [12]) were not selected 
as predictors.
LV diastolic dysfunction is reportedly an independent 
predictor of mortality in patients with acute MI [23] and 
in patients with HF [5, 24]. LV diastolic dysfunction was 
also recently demonstrated to be an independent predic-
tor of mortality, even in patients with preserved LVEF [25, 
26]. However, in all of those studies, LV diastolic function 
was noninvasively evaluated using Doppler echocardiog-
raphy. Only our previous study demonstrated an associa-
tion between invasively determined LV diastolic function 
and subsequent HF and cardiac death [8]. In that study, we 
did not examine the role of IS as a predictor of events; the 
study endpoints in that study also differed from those in 
this study.
In addition, LVEF is another powerful predictor of prog-
nosis in patients with MI and in patients with HF [15, 27, 
28]. In the present study, the LVEF value of <50 % was not 
a predictor of the study endpoints. This might be caused by 
the incorrect setting of the threshold LVEF value to reflect 
LV systolic dysfunction. In the present study, an LVEF 
value <48 % predicts an absence of IS with negative pre-
dictive value of 100 %; however, its relatively low speci-
ficity means that many patients with LVEF >50 % had IS. 
Previous studies have also demonstrated that LVEF loses 
its power as a prognostic indicator as the LVEF increases 
[13, 29].
LVEF as a surrogate for lack of IS
Because the measurement of IS requires left-sided cardiac 
catheterization using a catheter-tipped micromanometer, 
we tried to identify a surrogate for the presence or absence 
of IS by measuring LVEF, a standard clinical parameter of 
LV systolic function. The ROC curve analysis indicated 
that LVEF had significant potential for identifying the pres-
ence or absence of IS. The LVEF value of 58 % should be 
a surrogate for whether or not left ventricles have signifi-
cant values of IS in patients with CAD and atypical chest 
pain. Furthermore, patients with LVEF ≥58 % had fewer 
incidents of subsequent ADHF and good prognosis. In con-
trast, LVEF ≥50 % did not correlate significantly with the 
endpoints. Although the low LVEF values are the prognos-
tic indicator, we found that the relatively high LVEF value 
of 58 % also has prognostic power in our patients. Thus, 
the presence of IS might be one reason why patients with 
higher LVEF have fewer incidents of ADHF. In the I-PRE-
SERVE study, which investigated the effect of irbesartan on 
cardiovascular events in patients with HF with preserved 
Fig. 5  A receiver operating characteristic (ROC) curve for the left 
ventricular ejection fraction (LVEF) to predict an absence of inertia 
stress (IS). The area under the curve (AUC) is 0.94 (p < 0.001). LVEF 
values of 57, 58, and 62 % were the candidate LVEF values that were 
able to predict whether the left ventricle had significant IS with bal-
anced high sensitivity and specificity. An LVEF value of 58 % had 
both highest sensitivity and highest specificity for this purpose. LVEF 
<48 % predicted an absence of IS with 100 % sensitivity, while LVEF 
>67 % predicted an absence of IS with 100 % specificity
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ejection fraction (EF), a significant relationship between 
LVEF and poor outcome was only observed in patient with 
LVEF <60 % [29]. The LVEF value of 60 % is similar to 
our results.
Clinical implications
Although HF with preserved EF accounts for more than 
one-half of all HF cases [12–14], effective treatments for 
patients with HF with preserved EF have not been estab-
lished [29–32]. Four large trials have studied the effects 
of drug therapy on HF with preserved EF: the Dig Sub-
Study [30], CHARM Preserved [31], PEP-CHF [32], and 
I-PRESERVE [29]. Those studies focused on patients 
with LVEF >40 or >45 %. In clinical settings, the LVEF 
value of 50 % is widely used to categorize patients with 
HF with preserved EF or reduced EF [12]. In the pre-
sent study, LVEF ≥50 % had no significant relation to 
subsequent ADHF or the combined endpoint of subse-
quent ADHF and all-cause deaths, while most patients 
with LVEF ≥58 % had IS and good prognosis. Thus, we 
believe that the meaningful LVEF value to distinguish HF 
patients with preserved LV systolic function from those 
with relatively reduced LV systolic function is 58 %. Our 
proposed threshold LVEF value of 58 % might be a step 
toward improving the currently difficult situation of treat-
ing patients that have HF with preserved EF. The stand-
ard drug therapy for HF with reduced EF might work in 
patients with LVEF <58 %.
Study limitation
There are several limitations in this study. First, we used 
contrast enhanced left ventriculography for the measure-
ment of LVEF. This methodology has potential sources 
of inaccuracy in the measurements of LV volumes, which 
are caused by irregularities of the surface of LV chamber 
with trabeculae, papillary muscles, and chordae tendineae. 
In addition, rapid injection of contrast material and/or spe-
cific effects of contrast material during left ventriculogra-
phy may have affected the LV volume measurements. LV 
volume quantification using cardiac magnetic resonance 
imaging is more precise method; however, in the view-
point of a simultaneous measurement of LV volume and 
LV pressure, we thought that left ventriculography using a 
catheter-tipped micromanometer was inevitable way. Sec-
ond, this was a retrospective outcome-observational study 
conducted at a single institution with a limited number of 
patients. Therefore, a prospective study with a large num-
ber of patients should be conducted to confirm the present 
findings; however, we believe that the obtained findings 
are important for understanding the pathophysiology of 
patients with HF with preserved EF.
Conclusion
Lack of IS is a predictor of future ADHF and all-cause 
mortality. An LVEF value ≥58 % could be used as a sur-
rogate indicator that left ventricles have IS. Patients with 
LVEF ≥58 % may experience lower incidences of future 
ADHF and mortality, and they should have good prognosis.
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